Aquestive Therapeutics (NASDAQ:AQST) Insider Sherry Korczynski Sells 8,750 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at $1,230,296.58. The trade was a 3.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Down 4.2%

Aquestive Therapeutics stock opened at $4.78 on Friday. The business’s 50-day moving average price is $4.39 and its 200 day moving average price is $4.26. The firm has a market cap of $599.94 million, a price-to-earnings ratio of -7.35 and a beta of 1.48. Aquestive Therapeutics, Inc. has a 52 week low of $2.93 and a 52 week high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. Equities analysts expect that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AQST shares. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.17.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AQST. AQR Capital Management LLC lifted its position in shares of Aquestive Therapeutics by 12.2% during the 1st quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock valued at $374,000 after buying an additional 14,025 shares in the last quarter. Geode Capital Management LLC increased its holdings in Aquestive Therapeutics by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock worth $6,545,000 after acquiring an additional 276,295 shares in the last quarter. Creative Planning raised its position in Aquestive Therapeutics by 15.3% during the second quarter. Creative Planning now owns 98,751 shares of the company’s stock worth $327,000 after acquiring an additional 13,130 shares during the period. JPMorgan Chase & Co. raised its position in Aquestive Therapeutics by 46.3% during the second quarter. JPMorgan Chase & Co. now owns 435,972 shares of the company’s stock worth $1,443,000 after acquiring an additional 137,956 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Aquestive Therapeutics by 35.0% during the second quarter. Rhumbline Advisers now owns 140,872 shares of the company’s stock valued at $466,000 after purchasing an additional 36,509 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.